<DOC>
	<DOCNO>NCT02548832</DOCNO>
	<brief_summary>Dyslipidemia , cardiovascular risk factor great importance whose prevalence increase last decade . Part components metabolic syndrome consensus far contemplate increased triglyceride reduce HDL-C part element classification , include mixed dyslipidemia . Currently fibrates , bezafibrate , drug whose utility treat hypertriglyceridemia fully proven , besides reduce risk coronary disease . However , although treatment safe , without risk ; increase prevalence adverse effect dose thereof increase join combination statin drug treatment mixed dyslipidemia long term . Among alternative therapy berberine , reduce cholesterol triglyceride may useful combination bezafribrato treatment mixed dyslipidemia option lower cost low frequency adverse event .</brief_summary>
	<brief_title>Effect Administration Combination Bezafibrate More Berberine Lipid Profile Patients With Dyslipidemia</brief_title>
	<detailed_description>Clinical trial , double-blind , simple random assignment parallel group . Three study group patient 30-60 year age diagnose mixed dyslipidemia failure control medical nutrition therapy , simple random assignment random number assign one three group : 1 . 20 patient receive berberine , 1500 mg / day 2 . Patients receive 20 bezafibrate 400 mg / day 3 . 20 patient receive combination berberine ( 1500 mg / day ) plus bezafibrate ( 400 mg / day ) They determine intervention : lipid profile ( total cholesterol , triglyceride , HDL-C , LDL-C , VLDL ) , weight , BMI , waist circumference , glucose , blood pressure , tolerability . Statistical analysis perform upon sample subject . Before start statistical analysis group proceed verify behavior distribution variable include Z Kolmogorov-Smirnov goodness fit . The distribution variables test catalog normal normal , define type statistical test would perform ( parametric non-parametric ) . However , base sample size , non-parametric test consider suitable application . The data obtain express present use measure central tendency dispersion quantitative ( mean standard deviation ) variables qualitative variable express frequency percentage .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>A . Men woman B . Accomplished age 30 60 year C. Diagnosis mix dyslipidemia establish meet follow criterion : Total cholesterol &gt; 200 mg / dL Triglycerides &gt; 150 mg / dL 27 D. BMI 25 kg / m2 39.9 kg / m2 , weight stable past three month , define variability lower body weight 5 % . E. No drug treatment lipid profile 3 month prior baseline . F. Women must ensure nonhormonal method avoid pregnancy study period G. write information consent A . Removal inform consent letter B . Loss monitor C. Presence serious adverse event D. Adherence treatment &lt; 80 % E. Consumption drug know lipid profile , glucose metabolism , blood pressure body weight intervention period influence F. Intolerance tolerability hypersensitivity compound use study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Berberine</keyword>
	<keyword>Bezafibrate</keyword>
</DOC>